By Roger Longman
It’s difficult to avoid drawing comparisons between the first two Big Pharma acquisitions of 2009. Both Pfizer Inc.’s acquisition...
Merck's acquisition of Schering-Plough is all about buying breathing room, relief from what looks to be a 4-year, 50% earnings decline as key products go generic. Moreover, the relief comes relatively inexpensively (unless J&J steps in with a counteroffer), a fact that reflects Schering's lack of strategic options. In this interview, Merck's R&D boss Peter Kim and chief strategist, Mervyn Turner, explain the key pipeline and marketing complementarities and cost-cutting possibilities which prompted the deal -- and how they plan to integrate the two businesses.
By Roger Longman
It’s difficult to avoid drawing comparisons between the first two Big Pharma acquisitions of 2009. Both Pfizer Inc.’s acquisition...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.